RxDoctor Payments Data

Andres Piatti, MD

Rheumatology · Brooklyn, NYNPI 1629289327

Payments from drug & device makers

$501in general payments, 2019–2025

Across 22 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$127
  • Amgen$106
  • GSK$98
  • Johnson & Johnson$89
  • UCB, Inc.$30
  • Scilex Pharmaceuticals Inc.$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$44889%
  • Education$5311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis6$127
Amgen5$106
GSK4$98
Johnson & Johnson3$89
UCB, Inc.1$30
Scilex Pharmaceuticals Inc.1$20
Biocon Biologics Inc1$16
E.r. Squibb & Sons, L.L.C.1$16

How this compares

$501 in reported general payments places this provider in the 30th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$268,532
Medicare patients
322
Services billed
10,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept89$628,737
Humira(Cf) PenAdalimumab56$422,904
RinvoqUpadacitinib51$345,069
Xeljanz XrTofacitinib Citrate37$216,077
ProliaDenosumab54$88,179
SimponiGolimumab14$83,244
KevzaraSarilumab19$79,736
Actemra ActpenTocilizumab14$66,077
Lidocaine304$60,968
Diclofenac Sodium575$43,778
Mycophenolate Mofetil46$28,804
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag15$26,369
RestasisCyclosporine15$9,063
RasuvoMethotrexate/Pf13$8,991
Hydroxychloroquine Sulfate334$8,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia$106$88,17954 claims
Johnson & JohnsonSimponi$89$83,24414 claims
Scilex Pharmaceuticals Inc.Colchicine$20$7,03357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 541 rheumatology providers in New York.

Other rheumatology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →